V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Medpace Holdings Executive Compensation (FY25)

MEDP · Cincinnati, OH · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
August Troendle
Latest say-on-pay support
=
May 15, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Medpace Holdings brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): May 19, 2026
12 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Medpace Holdings brief$1,500Get the executive brief
Velarion Member, one year
211 figures on this page: 204 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — August Troendle: $8,600,016 → $11,443,766 (33.1% higher)
CEO pay ratio: 107:1 → 133:1 (24.3% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Medpace Holdings' chief executive and what were they paid?
August Troendle, Chief Executive Officer and Chairman of the Board, received $11,443,766 in total compensation for fiscal 2025. Troendle's total moved 33.1% higher from the $8,600,016 reported for fiscal 2024.
What was Medpace Holdings' say-on-pay result?
Shareholders supported the say-on-pay proposal with 92.9% of votes cast for or against in favor at the meeting held May 15, 2026 for fiscal 2025.
Which companies are in Medpace Holdings' peer group?
The disclosed peer group includes Agilent Technologies, Inc., Bio-Techne Corporation, Bruker Corporation, Charles River Laboratories and Fortrea Holdings Inc., among others.
What is Medpace Holdings' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 133:1.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
August Troendle
Chief Executive Officer
◇◇◇———◇◇
Susan Burwig
Executive Vice President of Operations
◇◇◇———◇◇
Jesse Geiger
President
◇◇◇———◇◇
Stephen Ewald
General Counsel and Corporate Secretary
◇◇◇———◇◇
Kevin Brady
Chief Financial Officer
◇◇◇———◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
August Troendle
Chief Executive Officer
◇◇————◇◇
Susan Burwig
Executive Vice President of Operations
◇◇————◇◇
Kevin Brady
Chief Financial Officer
◇◇————◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
August Troendle
Chief Executive Officer and Chairman of the Board
◇◇—◇——◇◇
Susan Burwig
Executive Vice President, Operations
◇◇◇———◇◇
Jesse Geiger
President
◇◇◇———◇◇
Stephen Ewald
General Counsel and Corporate Secretary
◇◇◇———◇◇
Kevin Brady
Chief Financial Officer and Treasurer
◇◇◇———◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
August Troendle
Chief Executive Officer and Chairman of the Board
◇◇—◇——◇◇
Susan Burwig
Executive Vice President, Operations
◇◇—◇——◇◇
Jesse Geiger
President
◇◇—◇——◇◇
Stephen Ewald
General Counsel and Corporate Secretary
◇◇—◇——◇◇
Kevin Brady
Chief Financial Officer and Treasurer
◇◇—◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
August J. TroendleOPTION◇——◇—◇◇
Jesse J. GeigerOPTION◇——◇—◇◇
Kevin M. BradyOPTION◇——◇—◇◇
Stephen P. EwaldOPTION◇——◇—◇◇
Susan E. BurwigOPTION◇——◇—◇◇
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
August TroendleOption◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Kevin BradyRSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Jesse GeigerOption◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Susan BurwigOption◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Stephen EwaldOption◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Stephen Ewald
General Counsel and Corporate Secretary · Terms as described in the company’s compensation discussion · citing a 2026 filing
Equity acceleration on change in control◇
Excise tax treatment◇
Susan Burwig
Executive Vice President, Operations · Terms as described in the company’s compensation discussion · citing a 2026 filing
Equity acceleration on change in control◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Fred B. Davenport, Jr
Lead independent director
◇—◇———◇
Brian T. Carley
—◇◇———◇
Robert O. Kraft
—◇◇———◇
Cornelius P. McCarthy III
—◇◇———◇
Dani S. Zander
◇—◇———◇
Femida H. Gwadry-Sridhar
◇—◇———◇
August J. Troendle served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Stock ownership guideline: The Compensation Committee approved beneficial stock ownership guidelines equal to one times base cash compensation for all NEOs and directors.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agilent Technologies, Inc. A
  • Bio-Techne Corporation TECH
  • Bruker Corporation BRKR
  • Charles River Laboratories CRL
  • Fortrea Holdings Inc. FTRE
  • ICON plc ICLR
  • IQVIA Holdings Inc. IQV
  • Labcorp Holdings Inc. LH
  • Quest Diagnostics Inc. DGX
  • Revvity, Inc. RVTY
  • Sotera Health Company SHC

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 15, 2026=◇◇◇
2024May 16, 2025=◇◇◇
2023May 17, 2024=◇◇◇
2022May 19, 2023=◇◇◇
2021May 20, 2022=◇◇◇
2020May 14, 2021=◇◇◇
2019May 15, 2020=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- August Troendle (Chief Executive Officer and Chairman of the Board), FY2025 total compensation $11,443,766 (base salary $937,417) [exec_comp, SEC accession 0001668397-26-000012, filed 2026-04-01]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Medpace Holdings files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Medpace Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Medpace Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Medpace Holdings' disclosed peer group is defensible, who names Medpace Holdings back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
211 figures on this page: 204 cited to the filing that reported them, 7 calculated from figures it prints.
204 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001193125-26-230425
  2. 0001668397-26-000012
    2025 DIRECTOR COMPENSATION TABLE · Compensation Discussion and Analysis · Director Compensation · Grants of Plan-Based Awards · and 3 more sections
  3. 000166839726000012
    CEO Pay Ratio
  4. 0001193125-25-121801
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001668397-25-000043
    SUMMARY COMPENSATION TABLE · Summary Compensation Table
  6. 0001193125-24-143907
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001668397-24-000082
    SUMMARY COMPENSATION TABLE · Summary Compensation Table
  8. 0001668397-23-000036
  9. 0001668397-23-000023
    Summary Compensation Table
  10. 0001193125-22-156274
  11. 0001193125-21-162145
  12. 0001193125-20-148746
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Medpace Holdings executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/MEDP (accessed 2026).
Short form: data: Velarion

The Medpace Holdings brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Medpace Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Medpace Holdings discloses

The companies named in MEDP's own disclosed peer group.

Agilent Technologies, Inc.Bio-Techne CorporationBruker CorporationCharles River LaboratoriesFortrea Holdings Inc.IQVIA Holdings Inc.Labcorp Holdings Inc.Quest Diagnostics Inc.Revvity, Inc.Sotera Health Company

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy